Clincosm LogoSign in Get a demo

Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia

Sponsor
Imperial College London (Other)
Overall Status
Completed
CT.gov ID
NCT00230659
Collaborator
Hammersmith Hospitals NHS Trust (Other)
100
Enrollment
1
Location
47
Duration (Months)
2.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable.

We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state.

We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Blood sample to be taken.

Study Design

Study Type:
Observational
Time Perspective:
Prospective
Official Title:
Investigation of Coagulation Parameters in Hereditary Haemorrhagic
Study Start Date :
Aug 1, 2004
Actual Primary Completion Date :
Jul 1, 2007
Actual Study Completion Date :
Jul 1, 2008

Arms and Interventions

Arm Intervention/Treatment
HHT patients

Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.

Other: Blood sample to be taken.
Blood sample to be taken.
Controls

People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.

Other: Blood sample to be taken.
Blood sample to be taken.

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients with HHT and normal controls
    Exclusion Criteria:
    • Previous thrombosis, recent ill health

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Imperial College Hammersmith Campus London United Kingdom W12 0NN

    Sponsors and Collaborators

    • Imperial College London
    • Hammersmith Hospitals NHS Trust

    Investigators

    • Principal Investigator: Claire Shovlin, Imperial College London

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Imperial College London
    ClinicalTrials.gov Identifier:
    NCT00230659
    Other Study ID Numbers:
    • IC/CLS6
    First Posted:
    Oct 3, 2005
    Last Update Posted:
    May 29, 2015
    Last Verified:
    Sep 1, 2005
    Additional relevant MeSH terms:
    Telangiectasis
    Telangiectasia, Hereditary Hemorrhagic

    Study Results

    No Results Posted as of May 29, 2015